Indian Stock Market News, Equity Market and Sensex Today in India | Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Indian equity markets slip into red
Tue, 14 Oct 11:30 am

After opening firm, the Indian Indices slipped into red and have remained below the dotted line during the morning trading session. Majority of stocks are trading in red with realty and metal stocks leading the pack of losers. Only stocks from healthcare and capital goods sectors are witnessing buying interest.

The BSE-Sensex is trading down 65 points. The NSE-Nifty is trading down 26 points. However both midcap and small cap stocks are in favour. The BSE Mid Cap index is trading up 0.12% and the BSE Small Cap index is trading up 0.11%%. The rupee is trading at 61.24 to the US dollar.

Indian pharma stocks are trading mixed with Indoco Remedies and Divis laboratories being among the leading gainers in the pack, while Ipca labs and Panacea biotech are the leading losers. As per the financial daily, Ranbaxy laboratories, subsidiary in US Ranbaxy Inc is witnessing high resignations of the top management. Around 5 top executives including the country's head Venkatachalam Krishnan and other heads from various departments have resigned together in the last week. All these top heads were working with the company for more than 10 years. While no specific reason for this attrition is known so far. Reportedly, both the companies viz Sun pharma and Ranbaxy denied to comment on this development. One should note this move comes after few months the India' largest pharma company Sun pharma decided to acquire the former company.

Telecom stocks are trading mixed today. While Bharti Airtel is leading the gainers; Reliance Communications is among the top losers. As per a leading financial daily, the Bharti Airtel - Loop Mobile deal is now in limbo with the Department of Telecom (DoT) yet to clear the file. Loop has about 3 m customers in Mumbai and its license will expire on 29 November 2014. The company did not renew its license due to commercial reasons. Instead, it sold out to Bharti for Rs 7 bn earlier this year. However, the DoT has not cleared the sale as Loop still owes the department about Rs 8 bn. Bharti had asked Loop's customers to port out to its network by submitting KYC documents at its stores but the regulator TRAI had asked the company to stop the porting. As per TRAI, Bharti cannot force Loop's customers to port to the company's network at their own expense. Bharti has asked the government resolve the issue quickly. Bharti Airtel was trading up 1.5% at the time of writing.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

Read the latest Market Commentary


What else is happening in the markets today? Dig in...

Equitymaster requests your view! Post a comment on "Indian equity markets slip into red". Click here!

  

Related Views on News

SUN PHARMA Announces Quarterly Results (3QFY21); Net Profit Up 87.4% (Quarterly Result Update)

Feb 1, 2021 | Updated on Feb 1, 2021

For the quarter ended December 2020, SUN PHARMA has posted a net profit of Rs 19 bn (up 87.4% YoY). Sales on the other hand came in at Rs 88 bn (up 8.4% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

SUN PHARMA 2019-20 Annual Report Analysis (Annual Result Update)

Dec 11, 2020 | Updated on Dec 11, 2020

Here's an analysis of the annual report of SUN PHARMA for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of SUN PHARMA. Also includes updates on the valuation of SUN PHARMA.

SUN PHARMA Announces Quarterly Results (2QFY21); Net Profit Up 66.9% (Quarterly Result Update)

Nov 6, 2020 | Updated on Nov 6, 2020

For the quarter ended September 2020, SUN PHARMA has posted a net profit of Rs 19 bn (up 66.9% YoY). Sales on the other hand came in at Rs 86 bn (up 5.3% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

SUN PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Aug 6, 2019 | Updated on Aug 6, 2019

Here's an analysis of the annual report of SUN PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of SUN PHARMA. Also includes updates on the valuation of SUN PHARMA.

More Views on News

Most Popular

It's the Beginning of a New Bull Phase in Smallcaps (Profit Hunter)

Feb 24, 2021

Last time the smallcap index crossed 19k a big correction followed. Here's what makes it different this time.

Make Rs 5,000 Per Day Trading the Market (Fast Profits Daily)

Feb 25, 2021

In this video, I'll show you how to get started on the path to daily trading profits.

The Hidden Tesla in My Great Indian Wealth Project (Profit Hunter)

Feb 23, 2021

An Indian company founded three decades ago in a garage caught my attention...

Gold 65,000 and Silver 84,000 in 2022

Feb 26, 2021

In this episode of the Investor Hour, India's #1 trader, Vijay Bhambwani, talks to us about the stock market, his new targets for gold and silver, the best long-term investment opportunity, and a lot more.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

S&P BSE HEALTHCARE


Mar 8, 2021 (Close)

S&P BSE HEALTHCARE 5-YR ANALYSIS

COMPARE COMPANY

MARKET STATS